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1. ABSTRACT 
Disasters such as earthquakes are events that affect wide populations causing 
widespread consequences including psychosocial disruption, physical threat, massive 
psychological stress. Mental health professionals have been increasingly called upon to 
assist during these acute crises. 
Disasters deserve special attention among human traumas because the capacity to 
traumatize a great many individuals at once, being the most public of traumas, and thus 
offering unique opportunities to study human response to tragedy on any level. Because 
natural disasters are random events that expose unselected populations to trauma, they 
offer unique opportunities for researchers interested in studying subjects ‘triggered’ to a 
unique trauma, disentangling confounding issues of pre-existing risk for exposure to 
traumatic events. 
On April 6th 2009, at 3:32 am, an earthquake (Richter Magnitude 6.3) struck L’Aquila, 
Italy, a town with a population of 72,000 and a ‘local health’ (i.e. Azienda Sanitaria Locale) 
of 105,000 inhabitants. L’Aquila earthquake caused the death of 309 people, with more 
than 1600 individuals injured, among which 200 were severely injured and hospitalized, 
and 66,000 displaced. Many buildings collapsed in the town of L’Aquila: large parts of it 
were completely destroyed. 
In this thesis psychoneurobiology of stress caused by this traumatic event has been 
investigated through three studies on Brain-Derived Neurotrophic Factor (BDNF). The 
BDNF is a key mediator of neuronal plasticity, which stimulate a variety of cellular effects 
at the structural and functional levels that eventuate in the promotion of survival and 
differentiation of responsive neurons. Stress has been widely linked with alterations in the 
expression and functioning of BDNF in both animal and human clinical studies. 
The aim of the first study was to investigate plasma BDNF levels in a clinical population 
who survived to the L'Aquila 2009 earthquake, along with the post-traumatic spectrum that 
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considers not only full expression of Post-Traumatic Stress Disorder (PTSD) but also 
subthreshold manifestations such as partial PTSD. To do so a consecutive sample of 37 
outpatients referring to the National Mental Health Care Service in L’Aquila for anxiety or 
affective symptoms after the earthquake, was compared to 15 healthy controls matched 
for age and gender. Eleven patients were diagnosed as not having PTSD but a different 
pathological condition that justified the referral and 13 patients respectively were 
diagnosed as showing Full or Partial PTSD. The subjects without PTSD, but with anxiety 
or affective disorders, and subjects with full-blown PTSD showed lower BDNF level than 
subjects with partial PTSD and healthy controls. 
The aim of the second study was to investigate the clinical correlates of plasma BDNF 
levels in a clinical population showing PTSD symptomatology, along with the post-
traumatic spectrum. Assessments included: Structured Clinical Interview for DSM-IV Axis-I 
disorders Patient Version, Trauma and Loss Spectrum-Self Report (TALS-SR) for post-
traumatic spectrum symptoms and the Impact of Event Scale Revised (IES-R) for the 
PTSD symptomatology. Thirteen patients were diagnosed as showing Full PTSD and 13 
Partial PTSD. Different relationship pattern of BDNF vs. stress symptoms has been 
reported in partial and full PTSD samples. 
In the third study BDNF modifications in subjects that did not showed psychiatric 
symptoms or symptoms worsening despite having suffered relevant stress event have 
been investigated. We hypothesized that, in so far as no stress consequences or 
relapse/worsening appeared in subjects who suffered relevant stress, any BDNF variation 
could be due to stress exposure. To do so BDNF plasma levels have been evaluated in 
subjects who suffered the same stress event, i.e. a clinical and non clinical population 
exposed to the 2009 L’Aquila earthquake, in comparison to a population not exposed to 
relevant stress. Statistical difference has been observed for diagnosis factor (clinical 
samples vs. controls). A trend toward significance was seen for exposition factor (exposed 
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vs. not exposed subjects); exposition by diagnosis interaction did not reach statistical 
significance. The exposed clinical sample showed significant higher BDNF level than the 
not exposed. Lack of statistical difference between exposed and not exposed subjects 
suggests that no BDNF modification intervened after the stressful event, but: exposed 
samples show the highest BDNF levels and a trend toward significance was seen; 
possibility of a ceiling effect, with no possibility of exceed a possible maximum level in the 
control sample can be considered. Clinical sample shows instead room for stress related 
BDNF increase. If so a BDNF increase with neuroprotective adaptive aim after stress 
cannot be excluded. 
The findings of these studies add more insight on the mechanisms regulating BDNF 
levels in response to stress and further proofs on the utility of the distinction of PTSD into 
full and partial categories along the spectrum approach. 
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2. Introduction 
2.1. When a disaster can aid research 
Earthquakes, one of the major natural disasters, are unpredictable, uncontrollable, and 
may be highly destructive. 
The April 6, 2009 L’Aquila earthquake was the strongest seismic event to occur in Italy 
over the last thirty years with a magnitude of M = 6.3 at 3:32 local time. L'Aquila is a 
central Italy town with a population of 72,000 inhabitants and a health district catchment of 
about 105,000 people. This earthquake was the strongest event in a sequence of seismic 
events that had started a few months earlier (October 2008) and was followed by 
numerous aftershocks in the next weeks. This number of pre- and aftershocks is likely one 
of the most catastrophic aspects of this natural disaster, causing fear and expectations of 
an even more severe earthquake among the residences of the region. 
The earthquake caused 309 deaths and considerable damage to structures over an 
area of approximately 600 km2, including the urban center of L’Aquila and several villages 
in the mid-Aterno Valley. The seismic event injured more than 1600, 200 of them seriously 
hurt and hospitalized, and displaced 66,000 people. Five per cent of the population were 
trapped under the rubble with minor physical consequences, 15% lost at least an 
acquaintance. Many buildings were damaged; others, especially in the historic centre, 
were completely destroyed. The earthquake affected an area of approximately 5,000 km2, 
significantly damaging most economic activities and public facilities, such as hospitals and 
schools at all levels. The Italian government gave an official estimate of the cost, in terms 
of direct economic losses and reconstruction costs, of eight billion Euros. 
All residents suffered directly from the disaster to varying degrees, in terms of 
involvement in the event, e.g. closeness to the epicenter or financial loss as a result of the 
earthquake, and personal characteristics, e.g. gender or age. The displaced people found 
accommodation in hotels of the nearby towns, or in tents located in camps near the urban 
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area. Twelve months after the earthquake, only 25% of the population was able to return 
to their homes (Stratta et al., 2012; Dell’Osso et al., 2013). 
Disasters such as earthquakes are events that affect wide populations causing 
widespread consequences including psychosocial disruption, physical threat, massive 
psychological stress. Mental health professionals have been increasingly called upon to 
assist during these acute crises. Many studies show that disasters and other traumatic 
events have short- and long-term health consequences, especially as regards mental 
disorders (Alexander 1996; Carr et al. 1997; Yzermans et al. 2005; Bartels and 
VanRooyen 2009).  
Natural disasters deserve special attention among human traumas because the 
capacity to traumatize a great many individuals at once, being the most public of traumas, 
and thus offering unique opportunities to study the human response to tragedy at any 
level. Because disasters strike randomly, studies of disasters circumvent the limitations of 
research on trauma to individuals in the community, where risk for traumatic events is 
confounded with vulnerability to psychopathology (North, 1995). Natural disasters are 
random events that expose unselected populations to trauma, they offer relevant 
opportunities for researchers interested in studying subjects ‘triggered’ to a unique trauma, 
disentangling confounding issues of pre-existing risk for exposure to traumatic events. 
The magnitude and intensity of the L’Aquila earthquake made it a significant subject for 
the study of mental health effects of trauma because of the profound effects among its 
survivors, including persons with no pre-disaster psychiatric history (Stratta et al., 2012). 
In this thesis the results of a psycho-neurobiological investigation performed on the 
earthquake survivors are reported. The study toke therefore advantage from the possibility 
of studying the effect of the same stress event shared from all the subjects recruited. 
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2.2. Neurobiology of stress 
Stress involves activation of neurobiological systems that preserve viability through 
change or allostasis. Although they are necessary for survival, frequent neurobiological 
stress responses increase the risk of physical and mental health problems, perhaps 
particularly when experienced during periods of rapid brain development. 
The adaptive physiological response to acute stress involves a process, initially referred 
to as allostasis by Sterling and Eyer (1988), in which the internal milieu varies to meet 
perceived and anticipated demand. McEwen (2002) extended this definition to include the 
concept of a set point that changes because of the process of maintaining homeostasis. 
The responses to severe stress that promote survival in the context of a life-threatening 
situation may be adaptive in the short run. However, if recovery from the acute event is not 
accompanied by an adequate homeostatic response to terminate the acute adaptive 
response of stress mediators, the deleterious effects on psychological and physiological 
function, termed the “allostatic load,” occur. The allostatic load is the burden borne by a 
brain and body adapting to both physiological and psychological challenges. The concepts 
of allostasis and allostatic load link the protective and survival values of the acute 
response to stress to the adverse consequences that result if the acute response persists 
(McEwen and Stellar 1993; McEwen, 1998). 
The importance of acknowledging the protective, as well as the potentially damaging 
effects of the mediators of stress and adaptation, has led to the introduction of these two 
terms. “Allostasis,” regards the process of maintaining stability (homeostasis) by active 
means, namely, by putting out stress hormones and other mediators. On the other hand 
the “allostatic load” or “overload,” regards the wear and tear on the body and brain caused 
by use of allostasis, particularly when the mediators are dysregulated, i.e., not turned off 
when stress is over or not turned on adequately when they are needed (Figure 1). 
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Figure 1. Role of the brain in  
“Allostasis” and “allostatic load” in response to stressors (modified from McEwen, 1998). 
______________________________________________________________________ 
Environmental stress (home, work, 
neighborhood)
Major life events
Trauma, abuse
Individual differences
(genes, development, 
experience)
Perceived stress 
(threat, helplessness, 
vigilance
Behavioural 
responses
(e.g. fight or flight)
Physiologic 
responses
Allostatic load
Allostasis Adaptation
 
______________________________________________________________________ 
 
The brain is the organ of the body that interprets experiences as threatening or 
nonthreatening and which determines the behavioral and physiological responses to each 
situation. Besides the hypothalamus and brain stem, which are essential for autonomic 
and neuroendocrine responses to stressors, higher cognitive areas of the brain play a key 
role in memory, anxiety, and decision making. These brain areas are targets of stress and 
stress hormones, and the acute and chronic effects of stressful experiences influence how 
they respond (McEwen, 2007). 
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A number of neurotransmitters, neuropeptides, and hormones have been linked to the 
acute psychobiological response to stress (Charney, 2004). They have important 
functional interactions, and mediate the neural mechanisms and neural circuits relevant to 
the regulation of reward, fear conditioning, and social behavior. The roles of those 
neurotransmitters, neuropeptides, and hormones that have been shown to be significantly 
altered by psychological stress are resumed in Table 1. 
These mediators of the stress response are not however the only involved. For 
example, glutamate and neurotrophic factors, such as brain-derived neurotrophic factor, 
and neuropeptides, such as substance P and cholecystokinin, have to be considered. 
Longitudinal community- based surveys of successful adaptation to extreme stress should 
be considered to determine if markers such as these or others can be used to develop a 
measure of psychobiological allostatic load that will be of predictive value. 
 
  
12 
 
Table 1. The neurochemical response to acute stress (modified from Charney, 2004). 
Neurochemical Acute Effects Brain Regions 
 
Key Functional 
Interactions 
Association With 
Psychopathology 
Cortisol Mobilized energy, 
increased arousal, 
focused attention, fear 
memory formation, fear 
learning 
Prefrontal cortex, 
hippocampus, 
amygdala, 
hypothalamus 
Increases amygdale 
corticotropinreleasing 
hormone (CRH), 
increases hypothalamic 
CRH 
Unconstrained release 
leads to 
hypercortisolemia-
depression, 
hypertension, 
osteoporosis, insulin 
resistance, coronary 
vascular disease; 
overconstrained release 
leads to 
hypocortisolemia, seen 
in some PTSD patients 
Dehydroepiandrosterone 
(DHEA) 
 
Counteracts deleterious 
effects of high cortisol 
neuroprotection; has 
positive mood effects 
Largely unknown; 
hypothalamus 
Antiglucocorticoid 
actions 
Low DHEA response to 
stress may predispose 
to PTSD and depression 
and the effects of 
hypercortisolemia 
CRH Activated fear 
behaviors, increased 
arousal, increased 
motor activity, inhibited 
neurovegetative 
function, reduced 
reward expectations 
 
Prefrontal cortex, 
cingulate cortex, 
amygdala, nucleus 
accumbens, 
hippocampus, 
hypothalamus, bed 
nucleus of the stria 
terminalis, 
periaqueductal gray 
matter, locus coeruleus, 
dorsal raphe 
CRH-1 receptor 
anxiogenic, CRH-2 
receptor anxiolytic, 
increases cortisol and 
DHEA, activates locus 
coeruleusnorepinephrine 
system 
Persistently increased 
CRH concentration may 
predispose to PTSD and 
major depression; may 
relate to chronic 
symptoms of anxiety, 
fear, and anhedonia 
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Table 1. The neurochemical response to acute stress (continue). 
Neurochemical Acute Effects Brain Regions 
 
Key Functional 
Interactions 
Association With 
Psychopathology 
Locus coeruleus-
norepinephrine system 
 
General alarm function 
activated by extrinsic 
and intrinsic threat; 
increased arousal, 
increased attention, fear 
memory formation, 
facilitated motor 
response 
Prefrontal cortex, 
amygdala, 
hippocampus, 
hypothalamus 
 
Activates sympathetic 
axis, inhibits 
parasympathetic 
outflow, stimulates 
hypothalamic CRH 
Unrestrained functioning 
of locus coeruleus-
norepinephrine system 
leads to chronic anxiety, 
hypervigilance, and 
intrusive memories; 
some patients with 
PTSD, panic disorder, 
and major depression 
show evidence of 
heightened locus 
coeruleusnorepinephrine 
activity 
Neuropeptide Y 
 
Anxiolytic; counteracts 
the stressrelated effects 
of CRH and the locus 
coeruleus-
norepinephrine system; 
impairs fear memory 
Amygdala, 
hippocampus, 
hypothalamus, septum, 
periaqueductal gray 
matter, locus coeruleus 
Reduces CRH-related 
actions at amygdala, 
reduces rate of firing of 
locus coeruleus 
Low neuropeptide Y 
response to stress is 
associated with 
increased vulnerability to 
PTSD and depression 
Galanin 
 
Anxiolytic; counteracts 
the stressinduced 
effects of the locus 
coeruleus-
norepinephrine system; 
impairs fear conditioning 
Prefrontal cortex, 
amygdala, 
hippocampus, 
hypothalamus, locus 
coeruleus 
Reduces the anxiogenic 
effects of locus 
coeruleusnorepinephrine 
system activation 
Hypothesized low 
galanin response to 
stress is associated with 
increased vulnerability to 
PTSD and depression 
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Table 1. The neurochemical response to acute stress (continue). 
Neurochemical Acute Effects Brain Regions 
 
Key Functional 
Interactions 
Association With 
Psychopathology 
Dopamine 
 
High prefrontal cortex 
and low nucleus 
accumbens dopamine 
levels are associated 
with anhedonic and 
helpless behaviors 
Prefrontal cortex, 
nucleus accumbens, 
amygdala 
Reciprocal interactions 
between cortical and 
subcortical dopamine 
systems 
Persistently high levels 
of prefrontal cortical and 
low levels of subcortical 
dopamine activity are 
associated with 
cognitive dysfunction 
and depression; 
persistently low levels of 
prefrontal cortical 
dopamine are 
associated with chronic 
anxiety and fear 
Serotonin (5-HT) 
 
Mixed effects: 5-HT 
stimulation of 5-HT2 
receptors is anxiogenic; 
5-HT stimulation of 5-
HT1A receptors is 
anxiolytic 
Prefrontal cortex, 
amygdala, 
hippocampus, dorsal 
raphe 
 
High levels of cortisol 
decrease in 5-HT1A 
receptors 
Low activity of 
postsynaptic 5-HT1A 
receptors may 
predispose to anxiety 
and depression 
Benzodiazepine 
receptors 
 
Acute stress down-
regulation of cortical 
benzodiazepine 
receptors 
Prefrontal cortex, 
hippocampus 
May be relationship 
between decreased 5-
HT1A and decreased 
benzodiazepine receptor 
function 
Decreased cortical 
benzodiazepine 
receptors are associated 
with panic disorder and 
PTSD 
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Table 1. The neurochemical response to acute stress (continue). 
Neurochemical Acute Effects Brain Regions 
 
Key Functional 
Interactions 
Association With 
Psychopathology 
Testosterone 
 
Stress-induced 
decrease in assertive 
behavior and increase in 
depression 
Hypothalamus CRH decreases 
testosterone levels 
Decreased CSF 
testosterone levels are 
found in PTSD; 
testosterone 
supplementation is 
helpful for depressed 
men with low 
testosterone levels 
Estrogen 
 
Acute increases in 
estrogen may dampen 
hypothalamic-
pituitaryadrenal (HPA) 
and norepinephrine 
responses to stress 
Hypothalamus, 
hippocampus 
 
Estrogen increases 
function of 
benzodiazepine 
receptors and decreases 
function of 5-HT1A 
receptors 
Long-term increases in 
estrogen may down-
regulate 5-HT1A 
receptors and increase 
risk for depression and 
anxiety 
 
16 
 
As a matter of fact another way that stress hormones modulate function within the brain 
is by changing the structure of neurons. The hippocampus is one of the most sensitive and 
malleable regions of the brain. The role of this plasticity may be to protect against 
permanent damage, or it may enhance vulnerability to damage. Whatever the 
physiological significance of these changes, the hippocampus undergoes a number of 
adaptive changes in response to acute and chronic stress. 
There are many hormonal, neurochemical, and behavioral modulators of neurogenesis 
and cell survival including estradiol, insulin-like growth factor I (IGF-I), antidepressants, 
voluntary exercise, and hippocampal-dependent learning (Aberg et al., 2000; Czeh et al., 
2001; Trejo et al., 2001). Neurochemical systems that regulate neurogenesis and dendritic 
remodeling are summarized in Figure 2 and Table 2 and include excitatory amino acids, 
serotonin, norepinephrine, benzodiazepines, endogenous opioids, neurotrophic factors, 
such as Brain.Derived Neurotrophic Factor (BDNF), and IGF-I, as well as glucocorticoids. 
Exploration of the underlying mechanism for this remodeling of dendrites and synapses 
reveals that it is not adrenal size or presumed amount of physiological stress per se that 
determines dendritic remodeling, but a complex set of other factors that modulate neuronal 
structure (McEwen, 1999). 
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Fig. 2. Structural plasticity in hippocampus involving synaptogenesis (S), neurogenesis (N), and dendritic remodeling (D) involves 
multiple neurochemical systems (modified from McEwen, 2007). 
Neurochemical systems for
structural plasticity
1. Glutamate release and 
reuptake
2. NMDA receptor activation, 
blockade
3. Circulating glucocorticoids
involving both 
mineralocorticoid (MR) and 
glucocorticoid (GR) receptors
4. Serotonin
5. Noradrenalin
6. Endogenous opioids
7. Benzodiazepines
8. BDNF
9. IGF-1, ghrelin, leptin, insulin
 
18 
 
Table 2. Adrenal steroid actions on neurochemical systems in hippocampus (McEwan, 
2007) 
______________________________________________________________________ 
Extracellular glutamate 
Adrenalectomy prevents stress-induced rise of extracellular glutamate 
Glucortcoids increase extracellular glutamate 
Stress induces Glt-1, glutamate transporter 
NMDA receptors 
Glucocorticoids upregulate NR2A&B (NMDA) receptor subunit mRNA (372) 
Calcium currents 
Glucocorticoids increase calcium conductances 
Glucocorticoids downregulate calcium extrusion pump 
Adrenal steroids biphasically regulate voltage-induced calcium currents 
5-HT system 
Adrenal steroids are required for stress-induced serotonin turnover 
Adrenal steroids biphasically regulate 5-HT1A receptors 
GABA benzodiazepine receptors 
Differential regulation of GABAA receptor subunit mRNA levels by ADX and corticosterone 
Opioids 
Glucocorticoids reverse ADX decrease in dynorphin in dentate gyrus 
Glucocorticoids upregulate preproenkephalin mRNA in hippocampus 
______________________________________________________________________ 
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Regarding the cellular and molecular mechanisms underlying structural remodeling, 
adrenal steroids are important mediators of remodeling of hippocampal neurons during 
repeated stress, and exogenous adrenal steroids can also cause remodeling in the 
absence of an external stressor (Magarinos et al., 1999; Sousa et al., 2000). The role of 
adrenal steroids involves many interactions with neurochemical systems in the 
hippocampus, including serotonin, endogenous opioids, calcium currents, GABA-
benzodiazepine receptors, and excitatory amino acids (McEwen, 1999), as summarized in 
Figure 2 and Table 2 (McEwen and Chattarji, 2004). Central to all of these interactions is 
the role of excitatory amino acids, such as glutamate. Excitatory amino acids released by 
the mossy fiber pathway play a key role in the remodeling of the CA3 region of the 
hippocampus, and regulation of glutamate release by adrenal steroids may play an 
important role (McEwen, 1999). Chronic psychosocial stress in the tree shrew also 
downregulated a number of other gene transcripts associated with neurotrophic effects 
and cytoskeletal plasticity, including neurotrophic factors (Alfonso et al., 2004). 
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2.3. Neurotrophins family 
During the development of the central nervous system, neural connections are 
established and redefined through a series of development programs involving 
specification of axons and dendrites, growth processes, innervation of target cells, cell 
death, and synaptogenesis. Many of these developmental processes are regulated by 
proteins derived from the target cells, which signal in a retrograde manner through long 
distances from the distal axons to the neuronal bodies. Neurons depend for their survival 
on these interactions with target cells, which release specific proteins that play a crucial 
role in these interactions (Leibrock et al., 1989; Zweifel et al., 2005). These specific 
proteins are called neurotrophins, a family of proteins that include the brain-derived 
neurotrophic factor (BDNF). The first neurotrophin to be discovered was NGF,about 50 
years ago. Several studies demonstrated its involvement in the regulation of neuronal 
death, both in response to subsequent damage to the nervous system as well as during 
development (Perez-Polo et al., 1990). The dependence of many neurons on their target 
cells for normal development and the restricted neuronal specificity of NGF (mainly 
peripheral nervous system), suggested the existence of other neurotrophic factors. The 
structure of BDNF was reported in 1990, a neurotrophin that promotes the survival of 
neuronal populations located in the central nervous system, or neuronal populations 
directly connected to it (Barde, 1990). In the following years other neurotrophins with 
similar functions were identified, such as NT-3 (Hohn et al., 1990; Maisonpierre et al., 
1990) and NT-6 (Gotz et al., 1994). Neurotrophins are all small, basic, secretory proteins 
that allow the survival of specific neuronal populations. In its biologically active forms 
together show about 50% amino acid identity. The genes encoding neurotrophins are 
expressed not only during development but also in the adult, in a variety of tissues 
including the central nervous system. Each neurotrophin can signal through two different 
cell surface receptors: the Trk tyrosine kinase receptor and the p75 neu-rotrophin receptor. 
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Each Trk receptor is preferentially activated by one ormore neurotrophin:TrkA by NGF, 
TrkB by BDNF, and TrkC by NT-3. Although the long-term trophic effects of neurotrophins 
depend on gene regulation, the cytoplasmic effectors activated by neurotrophins also exert 
a wide range of more rapid actions, including morphogenetic and chemotropic effects on 
developing neurons, and modulation of neuronal excitability and synaptic 
transmission(Poo,2001; Chao,2003). 
Once the role of the neurotrophins as regulatory factors of neuronal survival and 
differentiation was properly described, new evidence indicated that they also acted as 
synaptic modulators. Synaptic activity regulates the synthesis, secretion, and action of 
neurotrophins. These, in turn, induce changes in the morphology and synaptic efficacy. 
Thus, the neurotrophins are involved in activity-dependent synaptic plasticity, and with 
long-term changes in the synaptic connections at a structural and a functional level (Poo, 
2001). Neurotrophins seem to be necessary for the maintenance of functional synapses, 
because their removal produces a reduction in synaptic connectivity between cultured 
neurons.  
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2.4. The Brain-Derived Neurotrophic Factor (BDNF) 
The Brain-Derived Neurotrophic Factor (BDNF), is a member of the neurotrophin family 
of polypeptide nerve growth factors, widely expressed in the developing and adult 
mammalian brain, identified as a key regulator of neuronal development within the central 
nervous system (Lo, 1996). During development neurotrophins also prevent the death of 
embryonic neurons (Barde, 1994). Neurotrophins are expressed in almost all neuronal 
populations in the central and peripheral nervous systems (Huang and Reichardt, 2001; 
Chao, 2003). 
In the central nervous system neurons, BDNF can increase the number of excitatory 
and inhibitory synapses, regulating axonal morphology, or directly promoting synapse 
formation. Additionally, BDNF promote the maturation and stabilization of the cellular and 
molecular components of neurotransmitters release, and this subsequently leads to an 
increase in the number of functional synapses. It regulates synapse maturation at the 
morphological, molecular, and functional levels. This role of BDNF in synapses is crucial 
not only during development but also for synaptic plasticity in the adult (Vicario-Abejón et 
al., 2002). In addition to the classic effects on neuronal cell survival, it can also regulate 
axonal and dendritic growth and guidance, synaptic structure and connections, 
neurotransmitter release, long-term potentiation, and synaptic plasticity. Its receptors may 
act as a point of convergence that might be involved in the integration of many 
environmental inputs. This can lead to alterations in neuronal circuitry and, ultimately, in 
behavior. BDNF can also produce long-term changes in the functionality of adult neurons 
through changes in transcription (Chao, 2003). Activity-dependent synaptic plasticity 
models, whether in the context of development or in the context of learning and memory, 
have long postulated the existence of extracellular signaling molecules which reinforce and 
stabilize the active synapses. The work of many laboratories has shown that BDNF met 
the two major criteria to be considered a mediator of this type: the production is regulated 
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by neural activity, and neurotrophic factors themselves have potent effects on signaling 
properties of target neurons (Lo, 1995). 
BDNF is the neurotrophin most widely distributed in the brain with particularly large 
quantities in the hippocampus and the cerebral cortex (Altar, 1999). It regulates neuronal 
development/survival, and controls several neurotransmitter systems (Lewin and Barde, 
1996). BDNF is produced both by central nervous system cells and by epithelial cells and 
circulating BDNF is stored by peripheral platelets, those serve as a ‘buffer system’ for 
BDNF. BDNF crosses the blood-brain barrier two-directionally, and there is controversial 
evidence concerning the correlation between central levels and blood levels of BDNF 
(Karege et al., 2002). Serum levels of BDNF have been found to be 200-fold higher than 
plasma levels (Rosenfeld et al., 1995); this difference between serum and plasma BDNF 
may be caused by the amount of BDNF contained by platelets (Fujimura et al., 2002). 
In relation to the cellular and molecular biology underlying cognitive functioning, several 
studies support the conclusion that BDNF plays a key role, given its participation in the 
processes of synaptic plasticity and learning. An increased expression of BDNF can have 
a positive effect on the generation of long-term potentiation (LTP) and memory (Lee and 
Silva, 2009). The role of BDNF in learning and memory was first demonstrated in studies 
at the cellular and molecular level. It has been shown that BDNF secretion is required for 
LTP and long-term depression (LTD), which are the cellular mechanisms underlying 
learning and memory (Poo, 2001; Aicardi et al., 2004). In relation to long-term memory, is 
noteworthy that BDNF is sufficient to induce the transformation of early phase LTP to late 
phase LTP, even in the presence of protein synthesis inhibitors (Lu et al., 2005). In animal 
models, the role of BDNF in cognition has also been shown in studies with BDNF mutant 
mice that show learning deficits and hippocampal-dependent altered pattern discrimination 
(Korte et al., 1996; Gorski et al., 2003). Inhibition of the signaling of BDNF also alters long-
term memory in animal models (Lu et al., 2005). 
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The Brain-Derived Neurotrophic Factor (BDNF) in recent years has been proposed as a 
candidate to explain part of the pathogenesis, development and treatment of a number of 
psychiatric disorders, including schizophrenia (Galderisi et al., 2005; Carlino et al., 2012; 
Nieto et al., 2013), mood disorders (Post, 2007; Dell’Osso et al., 2010), anxiety (Kobayashi 
et al., 2005; Ströhle et al., 2010), eating disorders (Hashimoto et al., 2005; Nakazato et al., 
2012; Monteleone and Maj, 2008). Alterations in neurotrophic factors such as BDNF at the 
protein and gene level may contribute to altered brain development, synaptic 
disconnectivity, and failures in neuroplasticity,  different elements that provide evidence 
that BDNF may play a role in pathogenesis of these mental disorders, playing a role in the 
pathophysiology and symptoms.  
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2.5. BDNF and stress 
Smith et al. (1995) first demonstrated the role of neurotrophins in changes related to 
stress, and reported that stress decreases gene expression of BDNF in the hippocampus 
CA3 pyramidal cell layers and in the dentate gyrus granule cell layer. Since then, evidence 
has been produced demonstrating the complex outcome of stress on the BDNF system. 
Several authors have investigated the expression of BDNF in animal models that 
reproduce exposure to adverse life events. The initial observation of Smith et al. (1995) 
reporting reduced BDNF expression in the rat hippocampus after chronic immobilization 
stress has been confirmed by several subsequent studies (Nair et al., 2007; Roceri et al., 
2002; Vollmayr et al., 2001). Additionally, stress-induced down-regulation of hippocampal 
BDNF expression was observed not only after physical, but also following psychological 
stress (Rasmusson et al., 2002).  
The susceptibility to such events may depend upon the type and timing of the 
manipulation. Indeed we have shown that strong stressors, such as maternal separation, 
can reduce BDNF expression in the rat hippocampus (Roceri et al., 2002), although more 
protracted manipulations during gestation or the early phase of postnatal life do not 
produce significant changes on hippocampal BDNF levels. The length of the manipulation 
appears to be more important than the timing for changes that might occur at cortical level. 
Prenatal stress as well as repeated maternal separation determine a significant reduction 
of BDNF levels in prefrontal cortex of adult animals (Fumagalli et al., 2004; Koo et al., 
2003; Roceri et al., 2004), whereas a single maternal deprivation did not elicit any change 
on cortical neurotrophin expression (Roceri et al., 2002). Hence developmental events can 
have enduring effects on BDNF expression that, based on its role in information 
processing as well as on cognition, may contribute to the persistent changes on brain 
function and their relative contribution to psychopathology. 
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The long-lasting nature of neurotrophin changes appears to be due epigenetic 
mechanisms. Early maltreatment  elicited a reduction of BDNF mRNA levels in prefrontal 
cortex of adult offspring, which was associated with an increased methylation of the Bdnf 
gene on specific promoters (Roth et al., 2009). These results could provide a molecular 
basis for enduring changes in neuronal plasticity that are associated with a reduced ability 
to turn on the transcription of activity-regulated genes, such as the neurotrophin BDNF. 
The expression of BDNF is also significantly affected by stress at adulthood, although 
the final outcome depends on several variables, particularly the duration of stress and the 
time elapsed between the end of the stressful experience and the sacrifice. Acute 
stressors can produce a rapid facilitation of the BDNF system. In fact a significant and 
transient increase of BDNF mRNA levels has been observed in the rat (Marmigere et al., 
2003) as well as in the prefrontal and cingulated cortex of rats (Molteni et al., 2001) and in 
the frontal lobe of mice (Molteni et al., 2009a) exposed to an acute restraint stress. The 
synaptic increase of mBDNF in response to the acute stress may be part of a cellular 
‘defensive strategy’ aimed at increasing the pool of the mature neurotrophin that, upon 
release, might interact with its high affinity receptor TrkB and promote synaptic function 
and cell survival (Bramham and Messaoudi, 2005; Chao et al., 2006). Interestingly the 
increased synaptic levels of BDNF after stress are not observed in animal with a 
compromised function of glucocorticoid receptors (Molteni et al., 2009b), which represent a 
good model for susceptibility to depression (Ridder et al., 2005), suggesting that indeed 
rapid changes in BDNF under challenging conditions may reflect an active response 
strategy to preserve neuronal homeostasis (McEwen, 2008). Moreover, it has been 
recently demonstrated that glucocorticoids can also activate trkB receptor tyrosine kinases 
in vivo and in vitro, leading to neuroprotective effects (Jeanneteau 
et al., 2008), suggesting a further mechanism of integration between glucocorticoid 
hormones and neurotrophins. 
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If the rapid increase of BDNF expression following a single stress may represent a 
short-term protective mechanism, a prolonged stressful experience may have a 
detrimental effect on neuroplasticity, an observation supported by the overall negative 
impact of chronic stress on BDNF expression at hippocampal and cortical level.  
Reduced BDNF mRNA levels after different paradigms of chronic stress in rat prefrontal 
cortex (Fumagalli et al., 2004; Roceri et al., 2004) and in mouse frontal cortex (Fumagalli 
et al., 2003) have been found. Although the exact mechanism by which prolonged stressful 
experiences regulate BDNF is still unknown, the involvement of hormonal and 
neurotransmitter systems, has to be taken into consideration (Joca et al., 2007; Molteni et 
al., 2009a). 
Also chronic stress in adult life can alter the expression of BDNF, and in particular of 
some of its transcripts, through epigenetic mechanisms. Tsankova and collaborators 
(2006) have shown that chronic defeat stress down-regulated total hippocampal BDNF 
mRNA levels. Furthermore a prior history of stress can alter the pattern of changes 
produced by adult-onset stress on BDNF expression. For example, chronic immobilization 
stress reduced BDNF levels in the prefrontal cortex of ‘normal’ rats, while increasing its 
gene expression in prenatally stressed rats (Fumagalli et al., 2004). Similarly acute stress 
is not able to alter BDNF in rats previously exposed to MD (Nair et al., 2007; Roceri et al., 
2002). 
Stress causes damage and atrophy in the neurons in some brain regions, especially the 
hippocampus (Duman, 2004) in human also. Being an important structure for learning and 
verbal memory, the hippocampus also plays a pivotal role in the physiopathology of 
psychiatric disorders. It is known that the hippocampus has connections with the amygdala 
and prefrontal cortex (MacQueen et al., 2003). On the other hand, the negative modulation 
effect of the hippocampus on the hypothalamus-pituitary-adrenal stress hormone axis may 
be responsible for dysregulation of the stress response (Pittenger and Duman, 2007). Due 
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to stress there may be impairment in hippocampus-dependent memory. These changes 
can occur due to stress as well as glucocorticoids, and glucocorticoids may cause similar 
damage in the hippocampus (Sapolsky et al., 1985). In the hippocampus, increasing stress 
may inhibit neuronal growth (Gould et al., 1992) as well as cause neuronal death 
(Magarinos et al., 1996). 
After exposure to chronic stress, in contrast to reduced hippocampal volume, volume 
increase of the amygdale has been observed (Frodl et al., 2003). There is not only an 
increase in volume, but also hyperactivity in the function of the amygdala, as demonstrated 
in functional imaging studies (Drevets et al., 1992). As the hippocampus is responsible for 
verbal memory and impairment in verbal memory occurs in hippocampal atrophy, the 
amygdale is responsible for learning and memory; however, with hyperactivity of the 
amygdala, amygdala-dependent fear learning increases excessively (Conrad et al., 1999). 
Moreover, changes in the amygdala do not reverse completely, even after the cessation of 
exposure to chronic stressor (Vyas et al., 2004). The difference between the effects of 
stress on the amygdala, and hippocampus and prefrontal cortex is significant. While both 
acute and chronic stress impairs hippocampal function, reduces the length and complexity 
of CA3 dendrites, and impairs neurogenesis, they also lead to enhanced amygdala-
dependent fear learning, increased length and complexity of amygdalar dendrites, and 
increased amygdalar volume (Pittenger and Duman, 2007). This shows that stress does 
not have a unique effect on brain structure and functions, but may have various effects in 
various brain regions. 
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2.6. Post-Traumatic Stress Disorder (PTSD) 
The development of maladaptive symptoms after exposure to extreme stress has been 
observed from longtime. Jacob Mendez Da Costa, eminent Philadelphia physician, 
described an eponymous condition resembling posttraumatic stress disorder (PTSD) 
among veterans of the American Civil War (Vaisrub, 1975). The relatively high prevalence 
of this condition among veterans of the Vietnam War (Card, 1987; Long et al., 1996; Beals 
et al., 2002) was one important impetus for the PTSD research over the last several 
decades. The diagnosis of PTSD was first included in the third edition of the Diagnostic 
and Statistical Manual of Mental Disorders III ed. (DSM, APA, 1980) in 1980; since then, 
significant advances have been made in its, recognition, measurement and management 
and considerable research effort has been directed towards the etiology, phenomenology, 
clinical and neuro-biological characteristics, and treatment of PTSD and related and 
common comorbid disorders (Van Der Kolk et al., 1996; Norris and Riad, 1997). Following 
this, epidemiological studies were carried out in several countries, which indicated that the 
lifetime prevalence of PTSD was around 10.1% (Kessler et al., 2012), characterized by 
high risk of suicidal, abusive and maladaptive behaviours (e.g. dangerous driving, 
aggressive or self-destructive behaviour, at-risk sexual encounters) (Friedman et al., 2011; 
Dell’Osso et al., 2013; 2012a). 
Over these thirty years diagnostic criteria have modified and evolved from DSM III until 
the recently published DSM5 (Dell’Osso and Rossi, 2013). The workgroup for Anxiety, 
Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorders of the task 
force for the DSM-5 excluded now PTSD from the Anxiety Disorders, leading to the 
creation of a new section: Trauma and Stress Related Disorders including all the 
disturbances whose aethiopathogenesis is related to a traumatic event. Within this section 
five new diagnoses have been added: Reactive Attachment Disorder, Disinhibited Social 
Engagement Disorder, Acute Stress Disorder, Other Specified Trauma and Stressor 
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Related Disorder. This change places the trauma at the centre of a variety of disorders, 
highlighting the different possible reactions to the events. 
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2.6.1. DSM diagnostic criteria for PTSD 
The traumatic event. In the DSM-III (1980), the Criterion A foresaw the exposition to “a 
recognizable stressful event that would provoke significant symptoms of illness in almost 
all individuals”. In the DSM-III-R (1987), the criterion was modified adding that the 
traumatic experience had to be “outside of the usual human experience” including however 
also less unusual stressors, such as accident involvement. Further connotation was added 
in the DSM-IV (1994) with elimination of the statement of a stressor that “would provoke 
significant symptoms of illness in almost all individuals” and subdivision in  two 
components: Criterion A1, objective, “the person experienced, witnessed, or was 
confronted with an event or events that involved actual or threatened death or serious 
injury, or a threat to the physical integrity of self or others” and Criterion A2, subjective, 
“the person’s response involved intense fear, helplessness, or horror”. This choice did not 
however add more sensitivity and specificity to the diagnosis. 
The DSM-5 changed Criteria A1 and A2 into a single Criterion A adopting a restrictive 
approach for the selection of traumatic events. The Criterion A now foresees the actual 
exposition to, or threat of, death, severe injury or sexual violence. The event may be either 
directly experienced, or the person can be direct witness of a traumatic event occurring to 
others, or become aware that the victim of a traumatic event is a family member or close 
friend. Testimony does not include exposure via electronic instruments, television, movies 
or photographs, unless it is linked to work activity. 
This further redefinition of the traumatic event in DSM 5 can be the answer to the 
difficulty in finding the right equilibrium between the need to limit the risk of an excessive 
number of diagnoses due to the lack of highly specific criteria with diagnostic sensitivity. 
Symptomatological criteria 
The DSM-IV-TR foresaw a symptomatological triad: reexperiencing (Criterion B), 
avoidance or emotional blunting (Criterion C) and an increase in arousal (Criterion D). 
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The validity of this symptomatological clusters structure was not however consistently 
confirmed. While re-experiencing, avoidance and hyperarousal retain their identity, a 
further fourth factor, although less defined was suggested by several studies. Several 
studies indicated emotional blunting (from DSM IV Criterion C), while other ones indicated 
dysphoria, a combination of a relative emotional blunting and symptoms of hyperarousal. 
The DSM-5 integrates these results leading to a symptomatological structure of PTSD  
of four criteria, Negative alterations in cognition and mood, which derives from the 
separation of some of the symptoms formerly present in Criterion C of the DSM-IV-TR and 
with other changes to the other criteria. This new symptomatological cluster (now Criterion 
D)  includes symptoms of emotional blunting of the DSM-IV-TR, emphasizing selected 
aspects, and two new symptoms, namely pervasive emotional state and persistent 
negative distorted blame of self or others about the cause or consequences of the 
traumatic event. 
The symptomatological structure of PTSD has gone therefore from three to four 
clusters, with the separation of Avoidance from Numbing, and the revision of several 
symptoms in order to better identify the disorder. The addition of aggressive (Criterion E1) 
and self-destructive (Criterion E2) behaviours, which were not foreseen, but which recent 
studies have shown are clearly correlated with PTSD: aggressive behaviours often 
manifest in family and social settings, and self-destructive behaviour, which ranges from 
substance abuse to maladaptive and suicidal gestures. 
Although not revolutionary, the DSM-5 represent however a forward progress in better 
definition of the disorder. 
There is great interest in the effect that proposed DSM-5 criteria will have on the 
prevalence rate of the disorder. To date only a few studies investigated the impact that the 
proposed DSM–5 criteria will have on prevalence rates among civilian or veteran samples 
(Calhoun et al., 2012; Elhai et al., 2012; Forbes et al., 2011). Forbes et al. (2011), 
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investigating the impact of requiring both active avoidance and numbing symptoms 
separately, showed a decrease in PTSD prevalence of 1-2% points on data collected 
using existing DSM-IV-TR criteria, in a sample of 835 traumatic injury survivors 3- and 12-
months post-injury. However, in a more recent study, Elhai et al. (2012) found that 
changes associated with DSM-5 resulted in a slight increase in the observed prevalence 
rates of the disorder in a non-clinical sample of 585 college students. Calhoun et al. 
(2012), investigated the concordance of proposed DSM-5 PTSD criteria with DSM-IV 
classification rules in a sample of 185 participants who were recruited for studies focused 
on trauma and health, and examined the optimal number of symptoms required for PTSD 
DSM-5 Criterion D and E. The authors found a stronger concordance to DSM-IV-TR and a 
better sensitivity and specificity with only 2 symptoms required for Cluster D and E instead 
of the three actually required by DSM-5. 
Recent study examining the concordance between DSM-IV-TR and DSM-5 PTSD 
criteria and the impact of the proposed DSM-5 criteria on the prevalence rates of PTSD in 
high-school students attending the last year of high school in the L'Aquila, approximately 
10 months after the earthquake on April 6, 2009, showed that DSM-5 seems to lead to a 
more restrictive approach to PTSD diagnosis due to the introduction of new 
symptomatological criteria structure (Carmassi et al., 2013). 
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2.6.2. Future directions for research 
Future key priorities for research in the PTSD field are in the area of neurobiology, in 
order to determine brain mechanisms underlying the possibility of successful response to 
treatment. The underlying success in treatment can be further elucidated, with the help of 
a variety of animal models. These studies will likely involve examination of changes in 
brain receptor, neurotransmitter systems and neuroplastic factors. 
Regarding to phenomenology and etiology areas, the validation of the PTSD and acute 
stress disorder constructs and their distinction from other disorders are important issues as 
well as to improve the understanding of genetic and other biological contributions to PTSD 
susceptibility and the complex interrelationships between these factors and life 
experiences. 
Increased knowledge of the PTSD patophysiology of would not only help develop new 
therapeutic targets and treatments with improved short- and long-term efficacy, but also 
identifying predictors of treatment response. Finally PTSD needs an operational definition 
of remission, since the ultimate goal of treatment is not merely reduction of symptoms, but 
full remission (Nemeroff et al., 2006). 
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2.7. Post-Traumatic Stress Spectrum 
The term posttraumatic stress disorder was introduced in an attempt to classify 
psychiatric sequelae that arise from the experience of severe trauma. But which kind of 
event can be considered as severe and traumatic to induce a PTSD? Terribly frightening, 
life-threatening, or otherwise highly unsafe experiences that involved physical harm or the 
threat of physical harm for self or others can have higher possibility to induce the disorder, 
but is this always the case? Debate around whether an event can be defined as traumatic 
has risen controversies, even leading to the suggestion to eliminate the stressor criteria, 
relying only on the symptomatological aspects of the disorder, as it happens for other 
mental illnesses. 
Numerous studies on clinical characteristics, epidemiology and neurobiology, carried 
out on persons suffering from PTSD have taken into account not only risk factors, 
resilience and course of disease, but also the complications of PTSD as well as the 
subclinical and partial forms, which are neither less relevant or invalidating than the 
syndrome with complete symptomology (Dell’Osso e tal., 2012; Stratta et al., 2012; 
Dell’Osso et al., 2011; Dell’Osso et al., 2009). 
Individual’s vulnerability, involving gene-environment interaction, is a relevant issue that 
have to be considered for the PTSD onset. Trauma therefore could be a necessary 
condition but not sufficient to the disorder development, other risk factors such as peri-
traumatic dissociation, peri-traumatic negative emotions, social support, likely playing a 
relevant role. The nature of the trauma, pre-existing psychiatric disorders, available 
support systems, age at the time of the traumatic experience and other factors predispose 
patients to a variety of psychiatric responses (Jung, 2004; Silva et al., 2000). Thus in a 
complex interaction between the nature and severity of trauma and the varying 
vulnerability of the victim, a spectrum of psychiatric symptoms emerges. Dimensional 
approaches to PTSD, similarly to what reported for other mental disorders, have been 
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developed and tested. Moreau and Zisook (2002) first conceptualized a multidimensional 
approach to PTSD also taking into account the controversies on the definition of the 
stressor criterion. 
Other than a spectrum based on the nature of the trauma, other spectra can be 
considered: one based on symptom severity (or diagnostic threshold) and another based 
on potential responses to trauma (Moreau and Zisook, 2002). 
With regard to a stressor criteria spectrum, the diagnostic nomenclature initially only 
recognized severe forms of trauma personally experienced. More recently, however, the 
person’s subjective response and events occurring to loved ones were included. This has 
greatly broadened the stressor criteria by leading to an appreciation of the range of 
precipitating stressors and the potential impact of “low-magnitude” events. 
Among the severity spectrum, studies that review diagnostic thresholds reveal 
significant prevalence of PTSD symptoms and impairment that results from subthreshold 
conditions. Comorbidity patterns suggest that when PTSD is associated with other 
psychiatric illness, diagnosis is more difficult and the overall severity of PTSD is 
considerably greater (Figure 3). 
Marshall et al. (2001) reviewed studies that demonstrated that subthreshold PTSD 
caused by various stressors was as common as full PTSD. Partial PTSD is a chronic and 
disabling syndrome of trauma victims, subjects with partial PTSD share relevant symptoms 
with those with the full blown disorder that deserve treatment, confirming other literature 
observation (Jeon et al., 2007). Subthreshold symptoms may represent a prodrome of the 
full syndrome or residual symptoms of PTSD in partial remission. Regarding the former 
possibility, individuals who react to trauma with dissociation are at elevated risk for later 
developing the full syndrome of PTSD (Yehuda, 1999). For many patients, mild symptoms, 
such as numbing of affect and irritability limited to the recollection of trauma, persist 
indefinitely. Even after treatment, many individuals with PTSD continue to suffer from 
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residual symptoms years after the full syndrome is no longer present (Marshall et al., 
2001). Although not yet empirically validated, individuals with residual symptoms may be 
more susceptible to developing the full syndrome after subsequent traumatic exposure 
than individuals with full symptom and functional recovery. Further complicating matters, a 
characteristic course of PTSD is fluctuating symptom severity, with persons meeting full 
criteria for diagnosis intermittently over the course of many years (van der Kolk et al., 
1996). 
Given that responses to trauma vary considerably, another possible spectrum includes 
trauma-related conditions. Traumatic grief, somatization, acute stress disorder and 
dissociation, personality disorders, depressive disorders, and other anxiety disorders all 
have significant associations with PTSD. One proposal for classification might include 
PTSD at the severe end of a spectrum of stress related disorders, with adjustment 
disorders at the other. The relative rareness of pure PTSD, compared to the presence of 
more complex forms, suggests that traumatic stress may precipitate a whole host of 
symptoms and conditions (Yehuda and McFarlane (1995). 
Consideration of the severity of symptoms and the range of stressors coupled with the 
various disorders precipitated by trauma should greatly influence scientific research 
Moreau and Zisook, 2002. 
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Figure 3. Spectrum approach to Stress-Related Disorders: Nature of Stressor; Symptom 
Severity or Diagnostic Thresholds; Response to Trauma (modified from Moreau and 
Zisook, 2002) 
_______________________________________________________________________ 
Nature of stressor 
Mild Moderate Severe
e.g. divorce, loss of job e.g. accident, grief           e.g. disaster, abuse,
combat
Response to trauma
Symptom severity threshold
 Partial Cluster A, B, C: Subthreshold 
PTSD
 Full Cluster A, B, C: PTSD
 Comorbidity: Complicated 
PTSD
Trauma related conditions
 Dissociative disorders
 Acute stress disorder
 Somatization
 Complicated grief
 Personality disorder
 Mood and anxiety disorders
______________________________________________________________________ 
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2.8. Spectrum approach to PTSD: the Trauma and Loss Spectrum Questionnaire 
(TALS-SR) 
In the framework of the Spectrum Project (a USA-Italy collaboration), clinicians and 
researchers of the Department of Psychiatry of the University of Pisa (Italy) developed and 
validated a questionnaire to assess the “posttraumatic spectrum”: the Trauma and Loss 
Spectrum-Self Report (TALS-SR). Similar to other spectrum measures developed by the 
Spectrum Project (www.spectrumproject.org), the TALS-SR explores the 
presence/absence of post-traumatic spectrum that might occur during the lifetime of an 
individual. The TALS-SR investigates stress response syndromes across three different 
dimensions: 1) the dimension of the potentially traumatic events, including from extreme to 
minor ones; 2) the dimension of the peri-traumatic reaction; 3) the dimension of the 
posttraumatic spectrum symptomatology, including the lifetime occurrence of isolated 
criterion and non-criterion symptoms and features associated with the DSM-IV-TR 
diagnosis of PTSD. 
The TALS-SR is based on a multidimensional approach to post-traumatic stress 
reactions that includes a range of threatening or frightening experiences, as well as a 
variety of potentially significant losses, to which an individual can be exposed. The revised 
stressor criterion of the DSM-5 specifies that besides witnessing someone’s death, 
learning about the death of a close friend or a relative can be considered to be traumatic 
when the actual or threatened death has been violent or accidental. In the last decades, 
increasing efforts were aimed at identifying whether syndromes of unresolved grief are a 
form of stress response (Maj, 2008; Zisook et al., 2010). A growing literature, in fact 
provides evidence that a minority of individuals (9-20%) who experience the loss of a close 
relative or significant other may report symptoms of unresolved grief that are associated 
with significant distress and impairment, heightened risk for depression, anxiety, alcohol 
and tobacco consumption, and suicidal ideation. Symptoms include emotions over the 
40 
 
death such as a sense of disbelief, anger, bitterness and preoccupation often associated 
with distressing intense thoughts, besides intense yearning and longing for the deceased. 
This condition, named Complicated or Traumatic Grief or, more recently, Prolonged Grief 
Disorder, is identified by symptoms of both separation and traumatic distress which are 
distinctive from other Axis I mental disorders, primarily Major Depression (Zisook et al., 
2010). Thus, the TALS-SR divides two specific sessions exploring loss events and 
potentially traumatic events. The second and third dimensions of the TALS-SR explore the 
spectrum of the peri-traumatic reaction and post-traumatic symptoms, respectively, that 
may ensue from either type of life events (those that entail exposure to a negative 
threatening like event and those that entail exposure to a significant loss). These 
dimensions provide a dimensional approach to the patient’s psychopathology by 
incorporating information related to soft signs, subthreshold symptoms and atypical 
manifestations that may cause serious distress, as well as a broad array of clinical 
features associated with trauma and loss events. All these manifestations are commonly 
seen in clinical populations, but, except for the core or criterion symptoms, are not 
mentioned in current psychiatric classifications. In line with the new perspectives of the 
DSM-V also feelings of guilt, anger and shame, besides those of fear, helplessness and 
horror were added. Somatic and psychic symptoms of anxiety, that might be experienced 
in the immediate aftermath of the trauma, are also investigated. Consistently with the new 
proposals of the DSM-5, no distinction is added between acute and post-traumatic stress 
reactions (Friedman et al., 2011). 
The TALS-SR also targets temperamental and personality traits that may constitute risk 
factors or prodromal symptoms of the disorder. Many researchers have postulated that 
personal variables (e.g., personality traits) or environmental factors (e.g., level of 
perceived social support) influence the specific patterns of PTSD expression. Self 
perception of changes in personality as a result of the traumatic experience is not 
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uncommon among patients with PTSD. For these reasons the TALS-SR includes a 
specific domain exploring personality characteristics and risk factors where it is also 
investigated whether the patient perceived a change in his/her personality after the trauma 
had occurred. Further, in line with the changes proposed in the new criterion E of the 
DSM-5 and accordingly with the growing evidence on reckless and maladaptive behaviors 
occurring in patients with PTSD, the TALS-SR includes a specific session addressing 
these symptoms (maladaptive coping). 
The spectrum approach also allows to identify relevant subclinical comorbidities that 
may contribute either to the “complex” presentation of PTSD (e.g., the DESNOS) or to the 
frequent complex behavioral outcomes and complications, such as self-harm behavior and 
suicidality, also addressed by the DSM-5. By means of a spectrum comorbidity approach 
we could in fact show the impact of subthreshold mood symptoms on suicidality in patients 
with PTSD (Dell’Osso et al., 2009), consistently with previous findings in patients with Axis 
I comorbidity (Simon et al., 2004). 
Perhaps no other diagnostic category has gone through as many alterations and 
permutations as has PTSD. Is not so far the time that  many investigators and clinicians 
considered PTSD a product of malingering or a form of personality disorder (Davidson and 
Foa, 1991). Over the last 30 or so years, however, the validity of PTSD has become well 
established and is currently considered one of the most prevalent and disabling psychiatric 
disorders in civilian and not only in military populations (Yehuda, 1999). An understanding 
of PTSD and stress-related conditions is in its infancy. This is not surprising given the fact 
PTSD was not recognized as a distinct diagnostic entity quite recently, in the 1980, by the 
DSM diagnostic classification. From that time this disorder has undergone continuous 
change as our understanding of PTSD is refined. 
Although consideration of PTSD spectrum has not been included in the DSM 5, the 
opportunity of further studies is warranted. The dimensional approach is however gaining 
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support and over the past decade, psychiatrists have proposed a number of such 
dimensions although they are not used in practice, partly because they are not sanctioned 
by the DSM. The APA claims that the final version of DSM-5 is a significant advance on 
the previous edition and that it uses a combination of category and dimensional diagnoses. 
The previously separate categories of substance abuse and substance dependence are 
merged into the new diagnosis of substance-use disorder. Asperger's syndrome is bundled 
together with a handful of related conditions into the new category called autism-spectrum 
disorder; and OCD, compulsive hair-pulling and other similar disorders are grouped 
together in an obsessive–compulsive and related disorders category. These changes 
could help research into common vulnerabilities (Adam, 2013). 
Dimensional assessments, such as the spectrum approach developed in the TALS-SR, 
may give substantial contributions for a better understanding of post-traumatic reaction 
and thus, for redefining PTSD. 
This thesis dissertation wish to be one of these studies. 
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3. Introduction to the experimental section 
The brain-derived neurotrophic factor (BDNF), is a key mediator of neuronal plasticity, 
which stimulate a variety of cellular effects at the structural and functional levels that 
eventuate in the promotion of survival and differentiation of responsive neurons (Huang 
and Reichardt, 2001; . Nagahara and Tuszynski, 2011). 
Stress has been widely linked with alterations in the expression and functioning of 
BDNF in both animal and clinical studies. Animal studies demonstrated that many different 
types of acute and chronic stress paradigms decrease the expression of BDNF in the 
hippocampus (Duman and Monteggia, 2006; Andero and Ressler, 2012). Similarly, in 
human studies, acute and chronic stress has been consistently related to inhibition of 
hippocampal BDNF synthesis and reduction in BDNF levels (Duman and Monteggia, 2006; 
Machado-Vieira et al., 2007; Savitz et al., 2007; Rakofsky et al., 2012). 
Post-Traumatic Stress Disorder (PTSD) represents the prototypical form of stress-
induced mental disorder, but only recently BDNF studies in patients with such a diagnosis 
have been performed. Results from these studies are however not consistent. Dell’Osso et 
al. (2009) explored BDNF plasma levels in patients with a DSM-IV-TR diagnosis of PTSD, 
showing significantly lower levels with respect to healthy control subjects. This result 
suggests the involvement of this neurotrophic factor in the pathophysiology of PTSD. 
However, Hauck et al. (2010) found an opposite trend  in serum of patients with acute 
stress disorder (ASD) or PTSD showing higher BDNF levels than controls. These authors 
suggested that an initial elevation of BDNF in early stages of trauma psychopathology, 
could be followed by reduction in BDNF levels as reported by Dell’Osso et al. (2009). 
Despite the changes observed in peripheral BDNF, no significant difference has been 
found in cerebrospinal fluid BDNF levels between patients with moderate PTSD and 
healthy controls (Bonne et al., 2011). Differences in treatment history, psychiatric 
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comorbidities, primary diagnosis, source (i.e. serum vs. plasma or cerebrospinal fluid), and 
recency of trauma exposure may explain these inconsistent results. 
Recent efforts have been oriented to explore the prevalence rates and impact of not 
only Axis I-DSM-IV-TR PTSD in individuals exposed to a traumatic event but also of partial 
or subthreshold forms. The concept of partial PTSD was introduced for those subjects who 
fulfill only a subset of the DSM-IV criteria (B, C and D) for PTSD (Weiss et al., 1992; Stein 
et al., 1997; Marshall et al., 2001; Breslau et al., 2004; Mylle and Maes, 2004; Hepp et al., 
2005). More recently, dimensional approaches to PTSD have also been developed that 
conceptualize post-traumatic stress reactions as consisting of three main dimensions: the 
nature of the stressor, the possible responses to trauma and the symptom severity 
(Dell’Osso et al., 2008; 2009a) 
The spectrum approach represents an important challenge to the PTSD construct, 
allowing to identify relevant subclinical comorbidities that may contribute either to the 
“complex” presentation of PTSD or to the frequent behavioral outcomes and 
complications, such as self-harm behavior and suicidality. Studies on partial PTSD agree 
in reporting significantly less symptoms severity and functional impairment than in patients 
with full-blown disorder, but significantly more than in no-PTSD subjects, with an 
associated need for treatment (Stein et al., 1997; Dell’Osso et al., 2011). 
In this thesis psychoneurobiology of stress in L’Aquila earthquake survivors has been 
investigated through four related studies on Brain-Derived Neurotrophic Factor (BDNF): 
1. : Plasma Brain-Derived Neurotrophic Factor in earthquake survivors with full and 
partial Post-Traumatic Stress Disorder. In this study the plasma BDNF levels in a clinical 
population who survived to the L'Aquila 2009 earthquake, along with the post-traumatic 
spectrum that considers not only full expression of Post-Traumatic Stress Disorder (PTSD) 
but also subthreshold manifestations such as partial PTSD has been investigated. The 
results of this study has been published (Stratta et al., 2013a). 
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2. Clinical correlates of Plasma Brain-Derived Neurotrophic Factor in full and partial 
Post-Traumatic Stress Disorder. In this study the clinical correlates of plasma BDNF levels 
in a clinical population showing PTSD symptomatology, along with the post-traumatic 
spectrum has been investigated. 
3. What does late BDNF increase mean? A pilot comparison study of clinical and non 
clinical samples exposed and not exposed to the earthquake. In this study the BDNF 
modifications in subjects that did not showed psychiatric symptoms or symptoms 
worsening despite having suffered stress event, compared to subjects not having suffered 
relevant stress, have been investigated. 
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4. Study 1: Plasma Brain-Derived Neurotrophic Factor in earthquake survivors 
with full and partial Post-Traumatic Stress Disorder 
The aim of the study is to investigate plasma BDNF levels in a clinical population who 
survived to the L'Aquila 2009 earthquake, along with the post-traumatic spectrum that 
considers not only full expression of PTSD but also subthreshold manifestations such as 
partial PTSD by means of  dimensional assessment. 
 
4.1. Methods 
4.1.1. Subjects 
A consecutive sample of 37 outpatients (24 women and 13 men; mean age±SD: 
45.7±11.7 years) referring for anxiety or affective symptoms after the earthquake, were 
recruited at the National Mental Health Care Service (NMHCS) facilities in L’Aquila. The 
recruitment was performed about two years after the traumatic event (July – December 
2011). 
Exclusion criteria were the following: current or lifetime diagnosis of organic mental 
disorder, schizophrenia, schizophreniform or other psychotic disorders, substance-related 
disorders, uncontrolled or severe medical conditions. At the time of BDNF evaluation all 
patients were treated with low doses of benzodiazepines and / or antidepressants as 
stated by Ethical Committee. No patients were treated with antipsychotics or mood 
stabilizers. 
Fifteen healthy control subjects with no current or lifetime DSM-IV-TR mental or use of 
psychotropic medication, age and gender matched were enrolled from general population 
of L’Aquila exposed to the 2009 earthquake (10 women and 5 men; mean age±SD: 
45.1±11.9 years). 
The Ethics Committee of the Azienda Sanitaria Locale of L’Aquila approved all 
recruitment and assessment procedures. All subjects included provided written informed 
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consent, after receiving a complete description of the study and having the opportunity to 
ask questions. 
4.1.2. Clinical assessment 
The assessment included: the Structured Clinical Interview for DSM-IV Axis-I disorders 
Patient Version (SCID-I/P, First et al., 1995). The SCID-I/P was administered to patients 
by a psychiatrist (PS) trained and certified in the use of the instrument. 
4.1.3. BDNF evaluation procedure 
Venous blood samples were taken in the morning (between 8:00 and 9:00 am) to avoid 
diurnal variations of BDNF levels (Piccinni et al., 2008). Blood was drawn into EDTA-
coated tubes that were kept on ice, centrifugated at 2000 × g for 10 min for separating 
plasma from cells and supernatant was stored at −80 °C until the analysis. To measure the 
amount of total BDNF, acidification and subsequent neutralization of the samples were 
followed before proceeding with the enzyme-linked immunosorbent assay (ELISA) 
protocol, according to manufacturer's instruction (Promega, Wallisellen, Switzerland). The 
well-plates were coated with anti-BDNF monoclonal antibody and incubated at 4 °C for 18 
h. The plates were then incubated in a blocking buffer for 1 h at room temperature, then 
samples were added. The samples and BDNF standards were maintained at room 
temperature under shaking for 2 hours, followed by washing with the appropriate buffer. 
The plates were successively incubated with anti-human BDNF polyclonal antibody at 
room temperature for 2 h, washed and incubated with anti-IgG antibody conjugated to 
horseradish peroxidase for 1 h at room temperature. The plates were incubated in 
peroxidase substrate and tetramethylbenzidine solution to produce a colour reaction. The 
reaction was stopped with 1 M HCl. The absorbance at 450 nm was measured with a 
microplate reader (iMark, Microplate reader, Bio Rad Laboratories) to determine BDNF 
values that are expressed as pg/ml. 
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4.1.4. Statistical analyses 
Due to the relatively small size of the samples and scarce gaussianity of variables, non 
parametric statistic was chosen. Kruskal-Wallis Test for comparisons among n samples 
and Mann-Whitney Test for post hoc planned analyses between two samples were used. 
All analyses yielding a p <0.05 were considered significant. 
 
4.2. Results 
By means of SCID interview, 13 patients were diagnosed as showing Full PTSD and 13 
patients as showing Partial PTSD (age 49.9+10.2, 10 women and 3 men and age 
44.4+13.6; 9 women and 4 men respectively); 11 patients (age - mean+SD - 42.3+10.3; 5 
women and 6 men) were diagnosed as not having PTSD but a different pathological 
condition that justified the referral (3 subjects with depressive episode, 5 with depressive 
episode in bipolar disorder, 3 with panic attack). No differences in sex distribution 
(X2=2.75, df=2, NS) or age (F=1.49, df=2,34, NS) were observed in these diagnostic 
categories. 
Non parametric comparisons among the four samples of subjects exposed to the 
earthquake showed significant difference for BDNF (Table 1). Post-hoc planned Mann-
Whitney Test reported that subjects with full-blown PTSD and subjects without PTSD, but 
with anxiety or affective disorders, have lower BDNF level than subjects with partial PTSD 
and healthy controls. Although not significant, a trend toward higher BDNF levels in 
subjects with partial PTSD than controls is also shown. 
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Table 1. Comparison of BDNF plasmatic levels (pg/ml, mean+SD) among patients 
categorizations (no PTSD, Partial PTD, Full PTSD) and healthy subjects, although 
exposed to the earthquake. 
Subjects Mean Standard Deviation 
No PTSD (n=11) 3650.64 1648.23 
Full PTSD (n=13) 3473.31 2073.22 
Partial PTSD (n=13) 6180.93 2348.30 
Healthy subjects (n=15) 6004.81 4100.28 
Kruskal-Wallis Test X2=18.76, df = 3, p=.0005 
Post hoc planned Mann-Whitney Test: 
No PTSD vs. Full PTSD Z=.67, NS No PTSD vs. Partial PTSD Z=3.10, p<.005 
No PTSD vs. Healthy subjects Z=2.31, .05 Full PTSD vs. Partial PTSD Z=3.51, p<.0005 
Full PTSD vs. Healthy subjects Z=2.60, 
p<.01 
Partial PTSD vs. Healthy subjects Z=1.63, 
p=.10 
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4.3. Discussion 
We report that patients with full but not Partial PTSD show reduced BDNF peripheral 
levels. The present results are in agreement with previous findings by Dell’Osso et al. 
(2009). In addition, the BDNF levels in patients with Partial PTSD can be in line with 
Bonne et al. (2011) who reported no significant difference between patients with moderate 
PTSD severity and healthy controls. On the other hand, an integration of this report with 
Hauck et al. (2010) findings and hypotheses is possible. In fact, our patients with Partial 
PTSD, whose evaluation has been made two years after the traumatic event, show the 
highest BDNF values, thus strengthening the hypothesis that BDNF level could increase in 
the close aftermath of the trauma and then progressively decrease. In addition, patients 
reported in the study by Hauck et al. (2010) with higher BDNF and more recent stress had 
also less severe symptoms, so that they could be assimilated to our subjects with partial 
PTSD. 
Thus, not only the closeness to the trauma could lead to a BDNF increase as Hauck et 
al. (2010) hypothesized, but the kind of PTSD  (i.e. partial and full-blown PTSD) also has 
to be considered. As BDNF peripheral level might parallel changes occurring at cerebral 
level, its trend to increase in plasma of patients with partial PTSD could be interpreted as a 
neuroprotective reaction to the stress and to the fully expression of PTSD. If so, in Partial 
PTSD only an initial BDNF increase could happen, followed by BDNF normalization over 
time. This hypothesis is confirmed by Dell’Osso et al. (2009) finding in full-blown PTSD 
patients of no significant difference between plasma BDNF levels of subjects who had 
experienced the trauma less or more than one year before the time of assessment. 
Alternative or integrative hypothesis of these data can be that BDNF level reflect PTSD 
severity, i.e. the severer the patient’s illness, the lower the biological parameter as 
previously observed in patients with depressive disorder (Dell’Osso et al., 2010a). As a 
matter of fact our evaluation has been made two years after the traumatic event. Although 
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speculatively, we may hypothesize that our patients with partial PTSD had full PTSD in the 
aftermath of the earthquake, although did not required psychiatric intervention likely due to 
contextual reasons that could change the perception of the disorder (Holzinger et al., 
2011); the only partial improvement of the disorder lead therefore these patients to the 
clinical observation. The normal level of BDNF of these patients could be the 
neurobiological expression of the clinical improvement. This hypothesis is consistent with 
previous reports from our research group of BDNF increase only in patients showing 
clinical improvement after antidepressant or electroconvulsive therapy (Piccinni et al., 
2008; 2009). 
Interpretation of our results should keep in mind some limitations of the study. The first 
limitation is represented by the relatively small sample size, not allowing further 
subgrouping, e.g. for gender, although no different distribution is observed among the 
clinical groups; however all the patients recruited were on similar low dosage of drugs and 
no patient presented comorbid psychiatric diagnoses that might have affected the results. 
The important issue of the source of sample (serum, plasma, CSF) must be considered 
regarding the possible relationship between BDNF and PTSD and the different 
interpretations of results. BDNF is found in both human serum and plasma, with serum 
reporting even 200-fold higher than plasma levels due to the amount stored in circulating 
platelets (Rosenfeld et al., 1995). Plasma BDNF therefore may be considered a more 
reliable marker of neurotrophin activity. 
BDNF is synthesized as a precursor protein (pro-BDNF) and then processed into two 
isoforms (truncated-BDNF and mature BDNF) (Carlino et al., 2012). Due to their well 
different biological functions they are able to elicit, their evaluation as well as they 
reciprocal ratios could add further insight on the meaning of BDNF on stress reactions. 
This issue also should be object of research. Several factors other than neurotrophins can 
influence the possibility of having stress spectrum symptoms: among these personality 
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characteristics (Campbell-Sills et al., 2006), social support (Ozbay et al., 2008), number 
and degree of concurrent stressors, genetic polymorphisms (Frielingsdorf et al., 2010; de 
Quervain et al., 2012), as well as other variables representing the neurobiological basis of 
the stress-related psychopathology (Charney, 2004). This is object of our ongoing 
research. 
It is not clear whether abnormal BDNF function is a marker of PTSD itself, or a marker 
of a neural vulnerability to PTSD, as hypothesized for mood disorders. 36 Based on our  
results it is reasonable to hypothesize that lack of BDNF response to stress could increase 
vulnerability to PTSD. 
Finally, our observations of a lower BDNF level in subjects with PTSD as well as in the 
mixed sample with anxiety and affective disorder, suggest the existence of a common 
pathophysiological mechanism; it is also possible that the high rates of comorbidity that 
exist among many of these disorders may account for the inability of plasma BDNF level to 
discriminate between these pathologic conditions. 
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5. Study 2: Clinical correlates of Plasma Brain-Derived Neurotrophic Factor in 
full and partial Post-Traumatic Stress Disorder 
In the first study on L’Aquila (Italy) earthquake survivors, using a sample categorization 
based on a dimensional approach of the disorder symptomatology, we found reduced 
BDNF level in subjects with full blown PTSD but not in those with partial PTSD (Stratta et 
al., 2013). 
The aim of the present study is to investigate the clinical correlates of plasma BDNF 
levels in a clinical population showing PTSD symptomatology, along with the post-
traumatic spectrum that considers not only full expression of PTSD but also subthreshold 
manifestations, such as partial PTSD, by means of a dimensional assessment. 
 
5.1. Methods 
5.1.1. Subjects 
A consecutive sample of 26 outpatients (19 women and 7 men; mean age±SD: 
47.15+12.12 years) referring for post-traumatic symptoms after the 2009 earthquake, were 
recruited at the National Mental Health Care Service (NMHCS) facilities in L’Aquila. The 
recruitment was performed about two years after the traumatic event (July – December 
2011). Eleven consecutive patients (age - mean+SD - 42.3+10.3; 5 women and 6 men) 
diagnosed as not having PTSD but a different pathological condition that justified the 
referral (3 subjects with depressive episode, 5 with depressive episode in bipolar disorder, 
3 with panic attack) were also evaluated. 
Exclusion criteria were the following: current or lifetime diagnosis of organic mental 
disorder, schizophrenia, schizophreniform or other psychotic disorders, substance-related 
disorders, uncontrolled or severe medical conditions. At the time of BDNF evaluation all 
patients were treated with low doses of benzodiazepines and / or antidepressants as 
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stated by Ethical Committee. No patients were treated with antipsychotics or mood 
stabilizers. 
5.1.2. Cinical assessment 
The assessment included: the Structured Clinical Interview for DSM-IV Axis-I disorders 
Patient Version (SCID-I/P) (First et al., 1995); the Trauma and Loss Spectrum-Self Report 
(TALS-SR) for assessing post-traumatic spectrum symptoms related to the April 2009 
earthquake (Dell’Osso et al., 2009); the Impact of Event Scale Revised (IES-R, Weiss and 
Marmar, 1997) for the PTSD symptomatology. 
The SCID-I/P was administered to patients by a psychiatrist (PS) trained and certified in 
the use of the instrument. On the basis of the SCID interview Full and Partial PTSD 
distinction has been made. A diagnosis of partial PTSD was assessed when criteria B and 
or C or D for DSM-IV were satisfied (Stein et al., 1997), while full blown PTSD subjects 
meet all the disorder criteria. 
Subjects were also asked to complete the symptomatological domains of the TALS-SR, 
referring to the last week condition. The TALS-SR explores a range of post-traumatic 
spectrum symptoms comprising emotional, physical and cognitive responses to the 
trauma, including re-experiencing it, avoidance and numbing, and arousal symptoms. 
According to the aims of the present study, subjects were asked to fulfill domains IV and 
over, referring to symptoms that occurred after the earthquake exposure. Domain IV 
(Items 59–76) includes a range of emotional, physical and cognitive responses to this 
event. Domain V (Items 77–85), Domain VI (Items 86–97) and Domain VIII (Items 106–
110) include re-experiencing, avoidance and numbing, and arousal symptoms 
respectively, Domain VII (Items 98–105) targets maladaptive coping. 
The IES-R is a widely-used scale with excellent psychometric properties, which 
assesses intrusion, avoidance and hyperarousal symptoms that characterize stress 
response syndromes during the week preceding the evaluation. 
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The Ethics Committee of the Azienda Sanitaria Locale of L’Aquila approved all 
recruitment and assessment procedures. All subjects included provided written informed 
consent, after receiving a complete description of the study and having the opportunity to 
ask questions. 
5.1.3. BDNF evaluation procedure 
The procedure utilized in this study was the same of the study 1. 
5.1.4. Statistical analyses 
Due to the small size of the samples and scarce gaussianity of variables, non 
parametric statistic was chosen. Kruskal-Wallis Test for comparisons among n samples 
and Mann-Whitney Test for post hoc planned analyses between two samples were used. 
Spearman’s rho for correlation analysis and chi-square test were also used. Spearman’s 
rho for correlation analysis and Fisher r-to-z transformation for comparison between 
correlations were also used. T test for independent samples was used for between group 
age comparison. All analyses yielding a p <0.05 were considered significant. 
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5.2. Results 
By means of SCID interview, 13 patients were diagnosed as showing Full PTSD and 13 
patients as showing Partial PTSD (age 49.9+10.2, 10 women and 3 men and age 
44.4+13.6; 9 women and 4 men respectively). No differences in sex distribution (X2=.65, 
df=1, NS) or age (t=1.17, df=24, NS) were observed. 
Regarding to BDNF levels, as seen in the study 1, non parametric comparisons among 
the four samples of subjects exposed to the earthquake showed significant difference for 
BDNF (Table 1). Post-hoc planned Mann-Whitney Test reported that subjects without 
PTSD, but with anxiety or affective disorders, and subjects with full-blown PTSD have 
lower BDNF level than subjects with partial PTSD and healthy controls. Although not 
significant, a trend toward higher BDNF levels in subjects with partial PTSD than controls 
is also shown. 
 
 
Table 1. Comparison of BDNF plasmatic levels (mean+SD) among patients 
categorizations (no PTSD, Partial PTD, Full PTSD) and healthy subjects, although 
exposed to the earthquake. 
Subjects Mean Standard Deviation 
No PTSD (n=11) 3650.64 1648.23 
Full PTSD (n=13) 3473.31 2073.22 
Partial PTSD (n=13) 6180.93 2348.30 
Healthy subjects (n=15) 6004.81 4100.28 
Kruskal-Wallis Test X2=18.76, df = 3, p=.0005 
Post hoc planned Mann-Whitney Test: 
No PTSD vs. Full PTSD Z=.67, NS No PTSD vs. Partial PTSD Z=3.10, p<.005 
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No PTSD vs. Healthy subjects Z=2.31, .05 Full PTSD vs. Partial PTSD Z=3.51, p<.0005 
Full PTSD vs. Healthy subjects Z=2.60, 
p<.01 
Partial PTSD vs. Healthy subjects Z=1.63, 
p=.10 
 
Patients with PTSD (full or partial) showed higher score in IES-R and TALS-SR score 
than subjects without PTSD. No significant difference was seen between partial of full 
PTSD (Table 2). 
 
 
  
58 
 
Table 2. Comparison of IES-R scores and TALS-SR domains among patients 
categorizations (no PTSD, Partial PTD, Full PTSD); values are expressed as mean+SD. 
 No PTSD 
(n=11) 
Full PTSD 
(n=13) 
Partial PTSD 
(n=13) 
Kruskal-Wallis 
Test (df=2) 
IES-R     
Intrusions a .71+.72 2.15+.89 1.60+.92 X2=11.99 p<.005 
Avoidance b .95+1.05 1.75+.75 1.36+.80 X2=6.95 p<.05 
Hyperarousal c .85+.89 1.97+.81 1.68+.96 X2=9.88 p<.01 
Total score d .84+.77 1.96+.67 1.54+.81 X2=11.05 p<.005 
TALS-SR     
Domain IV 
Reaction to losses or 
upsetting events 
 
6.30+4.60 
 
8.92+2.14 
 
8.27+3.56 
 
X2=2.55 NS 
Domain V 
Re-experiencing e 
 
.80+1.40 
 
3.58+1.80 
 
3.27+2.00 
 
X2=13.14 p<.001 
Domain VI 
Avoidance and numbing f 
 
2.10+2.59 
 
4.50+2.25 
 
4.00+2.58 
 
X2=7.06 p<.05 
Domain VII 
Maladaptive coping 
 
.70+1.79 
 
.42+.49 
 
.73+.92 
 
X2=1.61 NS 
Domain VIII 
Arousal g 
 
1.50+1.56 
 
2.42+1.66 
 
3.09+1.75 
 
X2=5.40 p=.07 
Post hoc planned Mann-Whitney Test: 
a
 No PTSD vs. Full PTSD Z=3.29, p<.001 No PTSD vs. Partial PTSD Z=2.27, p<.05 Full PTSD vs. Partial PTSD Z=1.49, NS 
b
 No PTSD vs. Full PTSD Z=2.53, p<.01 No PTSD vs. Partial PTSD Z=1.51, NS Full PTSD vs. Partial PTSD Z=1.33, NS 
c
 No PTSD vs. Full PTSD Z=3.05, p<.005 No PTSD vs. Partial PTSD Z=2.27, p<.05 Full PTSD vs. Partial PTSD Z=.75, NS 
d
 No PTSD vs. Full PTSD Z=3.17, p<.005 No PTSD vs. Partial PTSD Z=2.15, p<.05 Full PTSD vs. Partial PTSD Z=1.44, NS 
e
 No PTSD vs. Full PTSD Z=3.13, p<.005 No PTSD vs. Partial PTSD Z=3.27, p<.001 Full PTSD vs. Partial PTSD Z=.29, NS 
f
 No PTSD vs. Full PTSD Z=2.50, p<.05 No PTSD vs. Partial PTSD Z=2.02, p<.05 Full PTSD vs. Partial PTSD Z=.62, NS 
g
 No PTSD vs. Full PTSD Z=1.35, NS No PTSD vs. Partial PTSD Z=2.27, p<.05 Full PTSD vs. Partial PTSD Z=1.17, NS 
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When correlations among variables were considered, no significant correlations were 
seen in the sample with PTSD symptoms (partial + full PTSD) and that with partial PTSD 
(Table 2). When we analyzed the sample with full-blown PTSD, a significant correlation 
emerged between BDNF level and TALS-SR IV domain (reaction to losses or upsetting 
events): (rho=.59, p<.05). The comparison of this correlation with that of the partial PTSD 
sample showed significant difference (Table 2). 
 
Table 2. Correlations (Spearman rho) between BDNF levels and TALS domains in full 
blown and partial PTSD subjects. 
 Plasmatic BDNF Correlation 
comparisona 
TALS-SR Full PTSD Partial PTSD z 
TALS Domain IV 0.59* -0.44 2.58** 
TALS Domain V -0.05 -0.09 0.09 
TALS Domain VI -0.23 -0.21 0.05 
TALS Domain VII 0.06 -0.31 0.57 
TALS Domain VIII 0.19 -0.25 0.13 
* p<0.05; ** p<0.001 
a 
Fisher r-to-z transformation 
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5.3. Discussion 
We observe that patients with full PTSD show reduced BDNF peripheral levels than 
those with partial disorder; in the previous related report on this clinical sample, full blown 
PTSD subjects only showed lower BDNF level than healthy control sample (Study 1 and 
Stratta et al., 2013). 
In front of this difference however, full blown and partial PTSD patients showed no 
different symptomatology as evaluated by TALS-SR. The result suggests that subjects 
with partial PTSD share relevant symptoms with those with the full blown disorder that 
deserve treatment, confirming other literature observation (Jeon et al., 2007). 
We found no correlation between BDNF levels and severity of symptoms in the total 
clinical sample (i.e. partial and full PTSD), in agreement with other observations (Berger et 
al., 2010; Bonne et al., 2011; Dell’Osso et al., 2009a; Hauck et al., 2010). Intriguingly 
enough, when the two samples were distinguished, the full blown PTSD sample showed a 
significant correlation between BDNF and stress symptoms: differently than in the partial 
PTSD sample, BDNF level strongly and positively correlated with TALS-SR IV domain (i.e. 
higher reaction to losses or upsetting events, higher BDNF: rho=.59). 
Although speculatively we hypothesize that this correlation could reflect a failure to cope 
stress, i.e. a ‘blunted’ stress-induced increase of the BDNF level. This ‘blunted’ BDNF 
response to stress could unveil and explain the counterintuitive association. On the other 
hand, in subjects with partial PTSD a stress-induced BDNF level increase is likely but, 
when the upper limit is reached, a sort of ceiling effect could cover possible correlations. 
Alternative or integrative hypothesis for interpretation of these data can be that the 
correlational pattern of full blown PTSD subjects is a feature of a phase that precede 
improvement, being the observed positive correlation a stress-induced effort of a BDNF 
increase. 
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The shared variance between BDNF level and the TALS domain, is not high, although 
not negligible. As a matter of fact we examined the relationship of BDNF with 
symptomatology only. Several other factors than neurotrophins can influence the 
possibility of modulating stress spectrum symptoms: among these personality 
characteristics, (Campbell-Sills et al., 2006) social support, (Ozbay et al., 2008) number 
and degree of concurrent stressors, genetic polymorphisms, (de Quervain et al., 2012; 
Frielingsdorf et al., 2010) as well as other variables representing the neurobiological basis 
of the stress-related psychopathology (Charney, 2004). These issues deserve further 
research. 
This is the first report on PTSD symptom correlates using a post-traumatic spectrum 
perspective. It is not clear whether abnormal BDNF function is a marker of PTSD itself, or 
a marker of a neural vulnerability to PTSD, as hypothesized for mood disorders 
(Hashimoto, 2010). Based on our results it is reasonable to hypothesize that lack or 
‘blunted’ BDNF response to stress could increase vulnerability to PTSD. 
Interpretation of our results should keep in mind however some limitations of the study. 
The first limitation is represented by the relatively small sample size, not allowing further 
subgrouping, e.g. for gender, although no different distribution is observed among the 
clinical groups. The subjects were being treated with drugs (benzodiazepines or 
antidepressants) that might affect the results; however all subjects were on similar low 
dosage and no patient presented comorbid psychiatric diagnoses. Other limitation is the 
use of a self-report instrument in the PTSD symptoms detection. Moreover there is more 
than one definition of partial PTSD in the literature; consistency however in results of 
epidemiological studies has been observed (Mylle and Maes, 2004). 
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6. Study 3: What does late BDNF increase mean? A pilot comparison study of 
clinical and non clinical samples exposed and not exposed to the earthquake 
Brain-Derived Neurotrophic Factor (BDNF) is among the most important within the 
neurotrophin family in cerebral synaptic plasticity and cognitive functions regulation. It is 
highly sensitive to environmental factors and its increase enhances neurogenesis, neurite 
sprouting, electrophysiological activity with beneficial effects on cognitive functions such as 
learning and memory (Bekinschtein et al., 2008; Murray and Holmes, 2011). Alterations in 
the BDNF expression and functioning has been widely linked with stress both in animal 
and clinical studies (Duman and Monteggia, 2006; Andero and Ressler, 2012; Machado-
Vieira et al., 2007; Savitz et al., 2007; Rakofsky et al., 2012). 
From a teleological perspective, synaptic modifications can be an adaptive process to 
adequate the organism to stress events, being BDNF a relevant modulator (Poo, 2001). It 
is precisely in the case of stressful events that greater information processing is needed in 
order to identify opportunities and possibilities to overcome the encountered difficulties. If 
the process is successful, the rapid BDNF capacity of performing cerebral modifications 
could avoid unwanted stress consequences and pathologies (McEwen, 2012; McEwen et 
al., 2012). On the other hand if no such neurotrophin and synaptic plasticity modifications 
append, pathological stress consequences could be result (Calabrese et al., 2009). 
In this study we aimed to investigate BDNF modifications in subjects that did not 
showed psychiatric symptoms or symptoms worsening despite having suffered relevant 
stress event. We hypothesized that, in so far as no stress consequences or 
relapse/worsening appeared in subjects who suffered relevant stress, any BDNF variation 
could be due to stress exposure. To do so we considered subjects who suffered the same 
stress event, i.e. a clinical and non clinical population exposed to a natural catastrophe 
(i.e. the 2009 L’Aquila earthquake) in comparison to a population not exposed to relevant 
stress. Because natural disasters are random events that expose unselected populations 
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to trauma, they offer unique opportunities for researchers interested in studying subjects 
‘triggered’ to a unique trauma, disentangling confounding issues of pre-existing risk for 
exposure to traumatic events. 
 
6.1. Methods 
6.1.1. Subjects 
Within a study on the predictivity of clinical and neurobiological factors on stress 
spectrum symptomatology (Stratta et al., 2013), here we considered healthy control 
subjects and depressed/anxious patients exposed to the earthquake and healthy control 
subjects and depressed/anxious patients not exposed to stress events. 
These populations were: 1) fifteen healthy control subjects with no current or lifetime 
DSM-IV-TR mental or use of psychotropic medication exposed to the L’Aquila 2009 
earthquake (10 women and 5 men; mean age±SD: 45.1±11.9 years); 2) a consecutive 
sample of 11 outpatients (age - mean+SD - 42.3+10.3; 5 women and 6 men), 8 with 
depressive episode and 3 with panic attack. These subjects were diagnosed before the 
earthquake and did not show worsening or relapse after the event. The control subjects 
shared with the clinical sample the stress due to the earthquake. The recruitment was 
performed about two years after the traumatic event (July – December 2011) at the 
National Mental Health Care Service facilities in L’Aquila; 3) a consecutive sample of 10 
outpatients (age - mean+SD 52.3+12.3; 5 women and 5 men) diagnosed as having 
depressive or panic attack disorders recruited at the Department of Clinical and 
Experimental Medicine of the University of Pisa; 4) thirty-seven healthy control subjects 
from Pisa (23 women and 14 men; mean age±SD 33.1+7.4 years), These two latter 
samples had not been exposed to the L’Aquila earthquake and exposition to traumatic 
events has been excluded. 
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At the time of BDNF evaluation all patients were treated with low doses of 
benzodiazepines and / or antidepressants as stated by Ethical Committees. No patients 
were treated with antipsychotics or mood stabilizers. 
The Ethics Committees of the Azienda Sanitaria Locale of L’Aquila and of the Azienda 
Ospedaliero - Universitaria of Pisa approved all recruitment and assessment procedures. 
All subjects included provided written informed consent, after receiving a complete 
description of the study and having the opportunity to ask questions. 
6.1.2. Procedures 
All subjects were assessed using the Structured Clinical Interview for DSM-IV Axis-I 
disorders Patient Version (SCID-I/P) (First et al., 1995). The Clinical Global Impression 
(CGI) measuring severity of illness was also used. 
The procedure utilized in this study for the BDNF evaluation was the same of the study 
1. 
6.1.3. Statistical analyses 
In order to control the gaussianity, BDNF values were log transformed. One-way and 
two-way Analysis of Variance (ANOVA) have been used. Main effects were further 
analyzed with post hoc planned t-test analysis. Chi square and Pearson’s r correlation 
were also used. All analyses yielding a p-value less than .05 were considered significant. 
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6.2. Results 
No significant difference has been seen in gender distribution across the four sample 
(X2=5.7, d.f. 3, NS). Different instead was the age (1-way ANOVA F=14.9, d.f. 3, p<.0005), 
but not significant correlation with BDNF was found. No difference for CGI severity of 
illness between exposed and not exposed clinical samples subjects (L’Aquila vs. Pisa) was 
found. No differences were observed between subjects with depression or panic attack 
disorders and these subjects were therefore considered in the same clinical samples.  
BDNF plasma levels for the four recruited samples are reported in Table 1. Statistical 
difference has been observed for diagnosis factor (clinical sample vs. controls F=15.2; 
p<.0005). Exposition factor (subjects exposed vs. not exposed to the earthquake F=2.9; 
p=.09) or exposition by diagnosis interaction (F=1.53; NS) did not reach instead statistical 
significance. Post hoc planned t-test showed significant difference between exposed and 
not exposed clinical samples (t=2.16, df 19, p<,05). 
 
Table 1. Comparison of BDNF plasmatic levels (pg/ml, mean+SD) and age between 
depressed / anxiety (dep/anx) patients and healthy subjects, exposed or not exposed to 
the earthquake. 
Subjects plasmatic BDNF Age 
dep/anx exposed (n=11) 3650.6+1648.2 42.2+10.2 
dep/anx not exposed (n=10) 2495.0+1335.9 52.3+12.3 
controls exposed (n=15) 6004.8+4100.2 46.3+10.6 
controls not exposed (n=37) 5526.2+2659.4 33.1+7.4 
two-way ANOVA for plasmatic BDNF after natural logarithm transformation  with 
exposition and diagnosis as factors and age as covariate 
exposition factor F=2.9; p=.09 
diagnosis factor F=15.2; p<.0005 
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exposition by diagnosis interaction F=1.5; p=.22 
 
6.3. Discussion 
The lack of global significant difference between the exposed and not exposed subjects 
indicate the acceptation the null hypothesis that no BDNF modification intervened after the 
stressful event. 
Some considerations however have to be made. Although not significantly, the exposed 
samples show the highest levels in absolute BDNF values with a trend for the exposition 
factor (p=.09) and significant difference has been found between the two clinical samples. 
The possibility of a ceiling effect cannot be excluded: it could be true for the healthy 
control sample, with no possibility of exceed a possible maximum level. If a ceiling effect 
could explain findings in controls, this is not the case for the clinical sample where the 
significant difference between exposed and not exposed samples is the double in size. 
Although BDNF decrease in subjects with affective disorders as well as panic disorder is a 
well reported finding (Lee et al., 2007; Piccinni et al., 2008; Pandey et al., 2010; Sözeri-
Varma et al., 2011; Kobayashi et al., 2005; Ströhle et al., 2010) further confirmed by our 
data, room however for a stress related increase seems to be possible. 
As BDNF peripheral level might parallel changes occurring at cerebral level, its trend to 
increase in plasma could be interpreted as a neuroprotective reaction to the stress. On the 
basis of these considerations, although speculatively, the higher BDNF levels of L’Aquila 
clinical and control samples than not exposed samples could be a residual ‘signal’ of the 
suffered stress and of a BDNF neuroprotective reaction with an adaptive aim. 
Some limitations should be considered in interpreting the results of the current study. 
The sample recruited is not large, but sufficient for a pilot study. We are aware that the 
control sample we studied is biased toward an exclusion of any symptom. By the same 
way the BDNF increase could be a correlate of resiliency. A further limitation is the 
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selection of comparison groups in a quasi experimental design where the samples are not 
equated prior to manipulation of the independent variable (i.e. earthquake exposure). Our 
evaluation has been made two years after the traumatic event; an initial BDNF increase 
therefore may have occurred in the aftermath of the stressful event, followed by BDNF 
normalization over time. 
Globally these findings add more insight on the mechanisms regulating BDNF levels in 
response to stress, delineating a landscape somewhat more complex than what could be 
expected from the somewhat inconsistent literature on PTSD alone (Dell’Osso et al., 2009; 
Hauck et al., 2010; Bonne et al., 2011; Stratta et al., 2013). 
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7. Conclusions 
From the observation of these studies, the role of BDNF as a versatile protein, key 
regulator of pathways which identify and responds to emotionally salient stimuli emerges. 
This is in line with previous results in literature (Rakofsky et al., 2012), but some 
interesting cues however can be added. 
The kind of the correlational patterns with stress related symptoms evaluation, as well 
as the comparison between subjects hit or not by a significant stressful event suggest that 
BDNF can be considered as a protective factor to stress. 
Different is the meaning of a protective vs. a compensatory mechanism in the stress 
literature (Luthar, 2006; Friborg et al., 2009). Protective mechanisms are dynamic 
developmental processes generated through successful engagement with adversities. On 
the other hand compensatory mechanisms involve resources that operate irrespective of 
stress levels. 
Along a protective model therefore resources are activated and adapt themselves in the 
face of adversity. This model can be consistent with our observations, BDNF operating in a 
dynamic process wherein individuals display positive adaptation despite experiences of 
significant adversity or trauma. 
Although speculatively, BDNF can be hypothesized as operate within an ‘immunity’ like 
process that can allow the person to overcome relevant salient stress. 
This ‘immunity’ terminology, relating to somatic disorders, are now commonly used in 
mental health research and clinical practice as a general term for the state of being not 
susceptible or resistant to a specific threat to wellbeing. The possibility of an immunity 
model can be considered in relation to mental well-being, involving psychological and 
biological mechanisms induced by significant stress. In this sense BDNF can be 
considered the protagonist of a compliant and dynamic system, such as an immune 
system that subsists in absence of a microbes’ attack, but reacts when is the case 
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increasing its coping abilities. The lack of possibility of an increase of BDNF level in front 
of a significant stressor would expose to the possibility of stress-related harms, such as 
PTSD. 
This immunity model has been recently considered at the basis of the resilience to 
stress (Davidov et al., 2010). The resilience approach can help to understand the 
constellation of interacting biological, psychological, social factors protecting from 
adversities (Bennett, 2008). Resilience involves intrinsic and extrinsic processes of 
successful adaptation to adversity. Because of the crucial importance of gene-environment 
interactions with various epigenetic, ‘plasticity genes’ and ‘meaning change’ mechanisms 
relating to resilience, a wide range of research strategies spanning psychosocial and 
biological methods is needed. 
Risk and protective processes operate at genetic, neurobiological, individual, and social 
levels, and do not act in isolation. The understanding of how these elements work together 
to promote resilience will advance by incorporating measures of endophenotypes and 
intermediate phenotypes using a system perspective to elucidate pathways from 
neurobiology to the coping to stressful events (Reich et al., 2010). 
BDNF is a candidate resilience element, associated with the ability to be adaptable and 
to cope flexibly with stress. Insight into biological factors underpinning resilience to stress 
may open new avenues for prevention and treatment of stress-related disorders (Charney, 
2004). Studies on the relationships between neurotrophic factors and resilience are 
therefore needed (Taliaz et al., 2011). 
Application of a ‘general immunity model’ as a common framework to stress research in 
mental health can help to clarify underlying mechanisms and challenges, which contribute 
to our understanding of health in general and mental health in particular. Such a common 
framework would help in the discussion of stress reaction in terms of multi-level defense 
barriers from transfer of adaptive (health) to maladaptive (disorder) reactivity, and a 
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balance of biological, psychological and social interactive effects for developing an 
adaptive trade-off between tolerance and sensitivity to stress. 
Globally the findings of this thesis can add more insight on the mechanisms regulating 
BDNF levels in response to stress, delineating a landscape somewhat more complex than 
what could be expected from the previous work (Dell’Osso et al.,2009). Moreover these 
data point at the utility of the distinction of PTSD into full and partial categories and to the 
spectrum approach to mental disorders. 
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